Well-being and co-morbidity in recent onset schizophrenia

999_cover.JPG

Thesis

Cover

Titlepage

Contents

General introduction

Introduction

Structure and aims of the thesis

Part I: Antipsychotic medication, subjective well-being, craving for and use of cannabis and discontinuation of antipsychotics

1.1: Adolescence, schizophrenia and drug abuse: a window of vulnerability

1.2: Effect of olanzapine and risperidone on subjective well-being and craving for cannabis in patients with schizophrenia or related disorders: a double blind randomized trial

1.3: Early withdrawal in a double-blind randomized clinical trial with olanzapine and risperidone performed in adolescents with first psychosis

1.4: Effect of early dysphoric response and cannabis use on discontinuation of olanzapine and risperidone in young adults with recent onset schizophrenia and related disorders

1.5: Improvement of subjective well-being and enduring symptomatic remission, a 5-year follow up of first episode schizophrenia

Part II: Obsessive-compulsive symptoms in recent onset schizophrenia

2.1: Obsessive-compulsive symptoms in a randomized double blind study with olanzapine or risperidone in youg patients with early psychoses

2.2: The catechol-o-methyltransferase gene and obsessive-compulsive symptoms in patients with recent onset schizophrenia

Part III: Insulin resistance in neuroleptic naive patients with recent onset schizophrenia

3.1: Hepatic insulin resistance in antipsychotic naive schizophrenic, schizo-affective patients, a detailed study of glucose metabolism with stable isotopes

General discussion, conclusions and implications

Summary

Samenvatting

Dankbetuiging

Curriculum Vitae